Research ArticlePDA Paper

Controls to Minimize Disruption of the Pharmaceutical Supply Chain During the COVID-19 Pandemic

T. Cundell, D. Guilfoyle, T. R. Kreil and A. Sawant
PDA Journal of Pharmaceutical Science and Technology July 2020, 74 (4) 468-494; DOI: https://doi.org/10.5731/pdajpst.2020.012021

References

  1. 1.↵
    FDA Drug Shortages Web site. https://www.fda.gov/drugshortages (accessed April 23, 2020).
  2. 2.↵
    U.S. Food and Drug Administration, Guidance for Industry: Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products, 2011. FDA Web site. https://www.fda.gov/media/120092/download (accessed May 14, 2020).
  3. 3.↵
    Medicines and Healthcare products Regulatory Agency, MHRA Regulatory Flexibilities Resulting from Coronavirus (COVID-19), 2020. GOV.UK Web site. https://www.gov.uk/guidance/mhra-regulatory-flexibilities-resulting-from-coronavirus-covid-19 (accessed May 14, 2020).
  4. 4.↵
    World Health Organization, Notice to Stakeholders—Frequently Asked Questions by the Manufacturing, Trial and Testing Organizations in Connection with Some of Their Constraints Faced during the COVID-19 Outbreak, 2020. World Health Organization Web site. https://extranet.who.int/prequal/sites/default/files/documents/Covid-19_Q-A_May2020.pdf (accessed May 14, 2020).
  5. 5.↵
    1. Wu J. T.,
    2. Leung K.,
    3. Leung G. M.
    Nowcasting and Forecasting the Potential Domestic and International Spread of 2019-nCoV Outbreak Originating in Wuhan China: A Modelling Study. Lancet 2020, 395 (10225), 689–697.
    OpenUrlCrossRefPubMed
  6. 6.↵
    World Health Organization, Coronavirus Disease (COVID-19) Pandemic. World Health Organization Web site. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed April 23, 2020).
  7. 7.↵
    1. Holshue M. L.,
    2. DeBolt C.,
    3. Lindquist S.,
    4. Lofy K. H.,
    5. Wiesman J.,
    6. Bruce H.,
    7. Spitters C.,
    8. Ericson K.,
    9. Wilkerson S.,
    10. Tural A.,
    11. Diaz G.,
    12. Cohn A.,
    13. Fox L.,
    14. Patel A.,
    15. Gerber S. I.,
    16. Kim L.,
    17. Tong S.,
    18. Lu X.,
    19. Lindstrom S.,
    20. Pallansch M. A.,
    21. Weldon W. C.,
    22. Biggs H. M.,
    23. Uyeki T. M.,
    24. Pillai S. K.
    ; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N. Engl. J.Med. 2020, 382, (10), 929–936.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Azar A. M. II.
    . Determination that a Public Health Emergency Exists, 2020. U.S. Department of Health and Human Services Public Health Emergency Web site. https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx (accessed April 23, 2020).
  9. 9.↵
    1. Trump D. J.
    Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19), 2020. White House Web site. https://www.whitehouse.gov/presidential-actions/proclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/ (accessed April 23, 2020).
  10. 10.↵
    1. Tellier R.,
    2. Li Y.,
    3. Cowling B. J.,
    4. Tang J. W.
    Recognition of Aerosol Transmission of Infectious Agents: A Commentary. BMC Infect. Dis. 2019, 19, (1), 101.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Guo Y.-R.,
    2. Cao Q.-D.,
    3. Hong Z.-S.,
    4. Tan Y.-Y.,
    5. Chen S.-D.,
    6. Jin H.-J.,
    7. Tan K.-S.,
    8. Wang D.-Y.,
    9. Yan Y.
    The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak—An Update on the Status. Mil. Med. Res. 2020, 7 (1), 11 https://doi.org/10.1186/s40779-020-00240-0.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Johns Hopkins University Center for Systems Science and Engineering. COVID-19 Dashboard, 2020. Johns Hopkins University & Medicine Coronavirus Resource Center Web site. https://coronavirus.jhu.edu/map (accessed April 30, 2020).
  13. 13.↵
    1. Yang Y.,
    2. Peng F.,
    3. Wang R.,
    4. Guan K.,
    5. Jiang T.,
    6. Xu G.,
    7. Sun J.,
    8. Chang C.
    The Deadly Coronaviruses: The 2003 SARS Pandemic and the 2020 Novel Coronavirus Epidemic in China. J. Autoimmun. [Online] 2020, 109, 102434. www.https://doi.org/10.1016/j.aut.2020.102434 (accessed April 23, 2020).
    OpenUrl
  14. 14.↵
    1. Kilbourne E. D.
    Influenza Pandemics of the 20th Century. Emerging Infect. Dis. 2006, 12 (1), 9–14.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Schaffner D. W.
    1. Ross T.
    Microbial Ecology in Food Safety Risk Assessment. In Microbial Risk Analysis of Foods; Schaffner D. W., Ed.; ASM Press, 2008; pp 51–98.
  16. 16.↵
    World Health Organization. Water, Sanitation, Hygiene, and Waste Management for the COVID-19 Virus: Interim Guidance, 2020. World Health Organization Web site. https://www.who.int/publications/i/item/water-sanitation-hygiene-and-waste-management-for-the-covid-19-virus-interim-guidance (accessed April 23, 2020).
  17. 17.↵
    1. Richman D.,
    2. Whitley R. J.,
    3. Hayden F. G.
    1. McIntosh K.
    Coronavirus. In Clinical Virology, 2nd ed.; Richman D., Whitley R. J., Hayden F. G., Eds.; ASM Press: Washington, DC, 2002; pp 1087–1096.
  18. 18.↵
    U.S. Equal Employment Opportunity Commission. Pandemic Preparedness in the Workplace and the Americans with Disabilities Act—Updated in Response to COVID-19 Pandemic, 2020. EEOC Web site. https://www.eeoc.gov/facts/pandemic_flu.html (accessed April 23, 2020).
  19. 19.↵
    U.S. Bureau of Labor Statistics. National Compensation Survey: Employee Benefits in the United States, March 2019, 2019, Table 31. U.S. Bureau of Labor Statistics of the United States Department of Labor Web site. https://www.bls.gov/ncs/ebs/benefits/2019/employee-benefits-in-the-united-states-march-2019.pdf (accessed Sep 24, 2019).
  20. 20.↵
    U.S. Equal Employment Opportunity Commission. What you should know about ADA, the Rehabilitation Act and the Coronavirus, 2020. EEOC Web site. https://www.eeoc.gov/wysk (accessed April 23, 2020).
  21. 21.↵
    1. Gandhi R. T.,
    2. Lynch J. B.,
    3. Del Rio C.
    Mild or Moderate COVID-19. N. Engl. J. Med. [Online early access] DOI: 10.1056/NEJMcp2009249. Published Online April 24, 2020. www.nejm.org/doi/full/10.1056/NEJMcp2009249 (accessed April 24, 2020).
  22. 22.↵
    Guidance on Preparing Workplaces for COVID-19; OSHA 3990-03 2020; 2020. U.S. Department of Labor Occupational Safety and Health Administration Web site. https://www.osha.gov/Publications/OSHA3990.pdf (accessed April 10, 2020).
  23. 23.↵
    World Health Organization. Management of Ill Travelers at Points of Entry—International Airports, Ports, and Ground Crossings—In the Context of COVID-19 Outbreak: Interim Guidance, 16 February 2020, 2020. World Health Organization Web site.
  24. 24.↵
    1. Priest P. C.,
    2. Duncan A. R.,
    3. Jennings L. C.,
    4. Baker M. G.
    Thermal Image Scanning for Influenza Border Screening: Results of an Airport Screening Study. PLoS One 2011, 6 (1), e14490.
    OpenUrlPubMed
  25. 25.↵
    1. Flasche S.,
    2. Eggo R. M.
    1. Quility B. J.,
    2. Clifford S.
    ; CMMID nCoV Working Group; Flasche S., Eggo R. M. Effectiveness of Airport Screening at Detecting Travellers Infected with Novel Coronavirus (2019-nCoV). Eurosurveillance 2020, 25 (5), 2000080.
    OpenUrl
  26. 26.↵
    1. Barnaby D. P.,
    2. Becker L. B.,
    3. Chelico J. D.,
    4. Cohen S. L.,
    5. Cookingham J.,
    6. Coppa K.,
    7. Diefenbach M. A.,
    8. Dominello A. J.,
    9. Duer-Hefele J.,
    10. Falzon L.,
    11. Gitlin J.,
    12. Hajizadeh N.,
    13. Harvin T. G.,
    14. Hirschwerk D. A.,
    15. Kim E. J.,
    16. Kozel Z. M.,
    17. Marrast L. M.,
    18. Mogavero J. N.,
    19. Osorio G. A.,
    20. Qiu M.,
    21. Zanos T. P.
    1. Richardson S.,
    2. Hirsch J. S.,
    3. Narasimhan M.,
    4. Crawford J. M.,
    5. McGinn T.,
    6. Davidson K. W.
    ; Northwell COVID-19 Research Consortium; Barnaby D. P., Becker L. B., Chelico J. D., Cohen S. L., Cookingham J., Coppa K., Diefenbach M. A., Dominello A. J., Duer-Hefele J., Falzon L., Gitlin J., Hajizadeh N., Harvin T. G., Hirschwerk D. A., Kim E. J., Kozel Z. M., Marrast L. M., Mogavero J. N., Osorio G. A., Qiu M., Zanos T. P. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized in the New York City Area. JAMA [Online early access] 2020, 323 (20), 2052–2059. DOI: 10.1001/jama.2020.6775. Published online April 22, 2020. (accessed April 22, 2020).
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Myers L. C.,
    2. Parodi S. M.,
    3. Escobar G. J.,
    4. Liu V. X.
    Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. JAMA [Online early access] 2020, 323 (21), 2195–2198. DOI: 10.1001/jama.2020.7202 Published online April 24, 2020. www.jama.com (accessed April 24, 2020)
    OpenUrlCrossRef
  28. 28.↵
    1. Kampf G.,
    2. Todt D.,
    3. Pfaender S.,
    4. Steinmann E.
    Persistence of Coronaviruses on Inanimate Surfaces and Their Inactivation with Biocidal Agents. J. Hosp. Infect. 2020, 104 (3), 246–251.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. van Doremalen N.,
    2. Bushmaker T.,
    3. Morris D. H.,
    4. Holbrook M. G.,
    5. Gamble A.,
    6. Williamson B. N.,
    7. Tamin A.,
    8. Harcourt J. L.,
    9. Thornburg N. J.,
    10. Gerber S. I.,
    11. Lloyd-Smith J. O.,
    12. de Wit E.,
    13. Munster V. J.
    Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N. Engl. J. Med. [Online early access] 2020, 382 (16), 1564–1567. DOI: 10.1056/NEJMc2004973. Published online March 17, 2020. nejm.org (accessed March 26, 2020).
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Rabenau H. F.,
    2. Cinatl J.,
    3. Morgenstern B.,
    4. Bauer G.,
    5. Preiser W.,
    6. Doerr H. W.
    Stability and Inactivation of SARS Coronavirus. Med. Microbiol. Immunol. 2005, 194 (1-2), 1–6.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Chan K. H.,
    2. Peiris J. S. M.,
    3. Lam S. Y.,
    4. Poon L. L. M.,
    5. Yuen K. Y.,
    6. Seto W. H.
    The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus. Adv. Virol. 2011, 2011, 734690.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Casanova L. M.,
    2. Jeon S.,
    3. Rutala W. A.,
    4. Weber D. J.,
    5. Sobsey M. D.
    Effects of Air Temperature and Relative Humidity on Coronavirus Survival on Surfaces. Appl. Environ. Microbiol. 2010, 76 (9), 2712–2717.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. van Doremalen N.,
    2. Bushmaker T.,
    3. Karesh W. B.,
    4. Munster V. J.
    Stability of Middle East Respiratory Syndrome Coronavirus in Milk. Emerging Infect. Dis. 2014, 20 (7), 1263–1126.
    OpenUrlCrossRefPubMed
  34. 34.↵
    EPA List N: Products with Emerging Viral Pathogens and Human Coronavirus Claims for Use against SARS-CoV-2: Date Accessed: 03/28/2020
  35. 35.↵
    U.S. Pharmacopeial Convention, General Chapter <1072> Disinfectants and Antiseptics. In USP 42—NF 37, USP: Rockville, MD, 2019.
  36. 36.↵
    U.S. Food and Drug Administration, Guidance for Industry—Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products during the Public Health Emergency (COVI-19). Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2020.
  37. 37.↵
    1. Cole E. C.,
    2. Cook C. E.
    Characterization of Infectious Aerosols in Healthcare Facilities: An Aid to Effective Engineering Controls and Preventive Strategies. Am. J. Infect. Control 1998, 26 (4), 453–464.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Pantelic J.
    Designing for Airborne Infection Control. ASHREA J. [Online] 2019. https://www.ashrae.org/file20library/technical20resources/covid-19/64-65_ieq_pantelic.pdf (accessed April 23, 2020).
  39. 39.↵
    1. Whyte W.
    Design of Unidirectional Cleanrooms and Clear Air Devices. In Cleanroom Technology: Fundamentals of Design, Testing and Operation; J. Wiley & Sons: Chichester, UK, 2001; Chapter 6, pp 71–89.
  40. 40.↵
    U.S. Pharmacopeial Convention, General Chapter <1115> Bioburden Control of Non-Sterile Drug Substances and Products. In USP 42—NF 37, USP: Rockville, MD, 2019.
  41. 41.↵
    U.S. Food and Drug Administration, Guidance for Industry and Food and Drug Administration Staff: Enforcement Policy for Face Masks and Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency (Revised) April 2020. FDA Web site. https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders (accessed April 10, 2020).
  42. 42.↵
    1. Hinton D. M.
    Rear Admiral, FDA. Letter to Mr. Bill Brodbeck, Steris Corporation—Emergency Use Authorization for the Steris Sterilization System for Decontaminating N95 Respirators, dated April 9, 2020.
  43. 43.↵
    1. Cohen J.
    Vaccine Designers Take First Shots at COVID-19. Science 2020, 368 (6486), 14–16.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    European Commission; Heads of Medicines Agency; European Medicines Agency, Notice to Stakeholders: Questions and Answers on Regulatory Expectations for Medicinal Products for Human Use during the COVID-19 Pandemic. EC, HMA, EMA: Brussels, 2020.
  45. 45.↵
    National Advisory Committee on Microbiological Criteria for Foods (NACMCF). Hazard Analysis and Critical Control Point Principles and Application Guidelines. J. Food Protection 1988, 61 (9), 1246–1259.
    OpenUrl
  46. 46.↵
    1. Alexander G. C.,
    2. Qato D. M.
    Ensuring Access to Medications in the US during the COVID-19 Pandemic. JAMA, J. Am. Med. Assoc. [Online early access]. DOI: 10.1001/jama.2020.6016. Published online Apr 9, 2020. https://jamanetwork.com (accessed April 11, 2020).
  47. 47.↵
    1. Sheikh K.
    Essential Drug Supplies for Virus Patients Are Running Low, 2020. The New York Times Web site. https://www.nytimes.com/2020/04/02/health/coronavirus-drug-shortages.html?searchResultPosition=2 (accessed Apr 11, 2020).
  48. 48.↵
    1. Lipsitch M.,
    2. Swerdlow D. L.,
    3. Finelli L.
    Defining the Epidemiology of Covid-19—Studies Needed. N Engl. J. Med. 2020, 382 (13), 1194–1196.
    OpenUrlPubMed
  49. 49.↵
    1. Barone P. W.,
    2. Wiebe M. E.,
    3. Leung J. C.,
    4. Hussein I. T. M.,
    5. Keumurian F. J.,
    6. Bouressa J.,
    7. Brussel A.,
    8. Chen D.,
    9. Chong M.,
    10. Dehghani H.,
    11. Gerentes L.,
    12. Gilbert J.,
    13. Gold D.,
    14. Kiss R.,
    15. Kreil T. R.,
    16. Labatut R.,
    17. Li Y.,
    18. Müllberg J.,
    19. Mallet L.,
    20. Menzel C.,
    21. Moody M.,
    22. Monpoeho S.,
    23. Murphy M.,
    24. Plavsic M.,
    25. Roth N. J.,
    26. Roush D.,
    27. Ruffing M.,
    28. Schicho R.,
    29. Snyder R.,
    30. Stark D.,
    31. Zhang C.,
    32. Wolfrum J.,
    33. Sinskey A. J.,
    34. Springs S. L.
    Viral Contamination in Biologic Manufacture and Implications for Emerging Therapies. Nat. Biotechnol. [Online] 2020, 38 (5), 563–572. https://www.nature.com/articles/s41587-020-0507-2 (accessed April 23, 2020).
    OpenUrl
  50. 50.
    1. Harcourt J.,
    2. Tamin A.,
    3. Lu X.,
    4. Kamili S.,
    5. Sakthivel S. K.,
    6. Murray J.,
    7. Queen K.,
    8. Tao Y.,
    9. Paden C. R.,
    10. Zhang J.,
    11. Li Y.,
    12. Uehara A.,
    13. Wang H.,
    14. Goldsmith C. S.,
    15. Bullock H. A.,
    16. Wang L.,
    17. Whitaker B.,
    18. Lynch B.,
    19. Gautam R.,
    20. Schindewolf C.,
    21. Lokugamage K. G.,
    22. Scharton D.,
    23. Plante J. A.,
    24. Mirchandandi D.,
    25. Widen S. G.,
    26. Narayanan K.,
    27. Makino S.,
    28. Ksiazek T. G.,
    29. Plante K. S.,
    30. Weaver S. C.,
    31. Lindstrom S.,
    32. Tong S.,
    33. Menachery V. D.,
    34. Thornburg N. J.
    ; Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States. Emerging Infect. Dis. 2020, 26 (6), 1266–1273.
    OpenUrl
  51. 51.↵
    1. Taleb N. N.
    The Black Swan: The Impact of the Highly Improbable; Random House: New York, 2007.
  52. 52.↵
    World Health Organization. The Top 10 Causes of Death, 2018. World Health Organization Web site. https//www.who.int/news-room/fact-sheets/detail/the–top-10-causes-of-death (accessed April 23, 2020).
  53. 53.↵
    CDC National Center for Health Statistics. Leading Causes of Death, 2017. CDC NCHS Web site. https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm (accessed April 23, 2020).
Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Controls to Minimize Disruption of the Pharmaceutical Supply Chain During the COVID-19 Pandemic
T. Cundell, D. Guilfoyle, T. R. Kreil, A. Sawant
PDA Journal of Pharmaceutical Science and Technology Jul 2020, 74 (4) 468-494; DOI: 10.5731/pdajpst.2020.012021
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords